[HTML] lww.com

[HTML][HTML] Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia

ML Hard, RJ Mills, BM Sadler, RZ Turncliff… - Journal of clinical …, 2017 - journals.lww.com
Background Aripiprazole lauroxil is an extended-release prodrug of aripiprazole for
intramuscular injection, approved for schizophrenia treatment. We developed a population …
被引用次数：49 相关文章 所有 7 个版本
[HTML] springer.com

[HTML][HTML] Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model

ML Hard, RJ Mills, BM Sadler, AY Wehr, PJ Weiden… - CNS drugs, 2017 - Springer
Background Aripiprazole lauroxil (AL) is a long-acting injectable medication approved for
the treatment of schizophrenia. Current AL regimens are 441 mg, 662 mg, and 882 mg …
被引用次数：42 相关文章 所有 9 个版本
[HTML] springer.com

[HTML][HTML] Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole …

ML Hard, AY Wehr, BM Sadler, RJ Mills… - European journal of …, 2018 - Springer
Abstract Background and Objectives Aripiprazole lauroxil (AL), a long-acting injectable
antipsychotic for the treatment of schizophrenia, requires 21 days of oral aripiprazole …
被引用次数：29 相关文章 所有 5 个版本
[HTML] springer.com

[HTML][HTML] Pharmacokinetics, safety, and tolerability of a 2-month dose interval regimen of the long-acting injectable antipsychotic aripiprazole lauroxil: results from a 44 …

PJ Weiden, Y Du, L von Moltke, A Wehr, M Hard… - CNS drugs, 2020 - Springer
Background Aripiprazole lauroxil (AL) is a long-acting injectable antipsychotic approved for
treatment of schizophrenia in adults. Approved AL doses and dosing regimens include 441 …
被引用次数：11 相关文章 所有 8 个版本
[HTML] lww.com

[HTML][HTML] Pharmacokinetic evaluation of a 1-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia

ML Hard, AY Wehr, Y Du, PJ Weiden… - Journal of Clinical …, 2018 - journals.lww.com
Background Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the
treatment of schizophrenia, requires 21 days of oral aripiprazole supplementation upon …
被引用次数：19 相关文章 所有 6 个版本

Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal …

R Turncliff, M Hard, Y Du, R Risinger, EW Ehrich - Schizophrenia research, 2014 - Elsevier
Aripiprazole lauroxil is a linker lipid ester of aripiprazole for extended-release intramuscular
(IM) injection. This multicenter, randomized, open-label study evaluated the …
被引用次数：54 相关文章 所有 7 个版本

Aripiprazole lauroxil: a review in schizophrenia

JE Frampton - Drugs, 2017 - Springer
Aripiprazole lauroxil long-acting injectable (LAI)[Aristada®] is an intramuscularly
administered, extended-release prodrug of aripiprazole, an established atypical …
被引用次数：21 相关文章 所有 5 个版本
[HTML] sciencedirect.com

[HTML][HTML] Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study

S Mallikaarjun, JM Kane, P Bricmont, R McQuade… - Schizophrenia …, 2013 - Elsevier
Abstract This 24-week, open-label, Phase Ib, parallel-arm, multiple-dose trial assessed the
pharmacokinetics, safety and tolerability of a once-monthly injection of aripiprazole …
被引用次数：108 相关文章 所有 10 个版本

Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil

L Citrome - Expert review of clinical pharmacology, 2016 - Taylor & Francis
Aripiprazole monohydrate (AM) and aripiprazole lauroxil (AL) are two different long-acting
injectable formulations of aripiprazole. AM 400 mg administered once monthly demonstrated …
被引用次数：42 相关文章 所有 3 个版本
[PDF] tandfonline.com

Aripiprazole plasma concentrations delivered from two 2-month long-acting injectable formulations: an indirect comparison

M Harlin, C Chepke, F Larsen… - Neuropsychiatric …, 2023 - Taylor & Francis
Abstract Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a novel long-acting
injectable (LAI) formulation of aripiprazole monohydrate for administration once every 2 …
被引用次数：4 相关文章 所有 11 个版本